Physician profile
Binh Tran
NPI 1184610602
$7,320.84
in general payments reported to CMS, 2019-2025
62 companies · $2,663 in 2025
The $2,663 reported for 2025 was more than what 92% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,738 · 2020: $647 · 2021: $212 · 2022: $515 · 2023: $531 · 2024: $1,016 · 2025: $2,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,209.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $803.48 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $679.14 | 2022-2025 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $660.67 | 2019-2025 | Imfinzi, Lynparza, Onglyza |
| Janssen Biotech, INC. | $626.58 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Genzyme Corporation | $511.65 | 2019-2023 | |
| Pfizer INC. | $418.82 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $272.32 | 2020-2025 | |
| Emd Serono, INC. | $244.90 | 2020-2025 | Bavencio |
| Regeneron Healthcare Solutions, INC. | $220.07 | 2019-2025 | Libtayo |
| Amgen INC. | $178.51 | 2019-2023 | Lumakras |
| Gilead Sciences, INC. | $163.83 | 2025 | Trodelvy |
| Eisai INC. | $163.10 | 2020-2025 | |
| Genentech USA, INC. | $153.72 | 2022-2025 | Polivy, Alecensa, Columvi |
| Takeda Pharmaceuticals U.S.A., INC. | $146.27 | 2020-2025 | Iclusig |
| Janssen Scientific Affairs, LLC | $143.95 | 2025 | Akeega, Erleada |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binh Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.